Drug Research
Benzodiazepine Drugs Market Set to Record US$ 2.6 Bn by 2026; the U.S. to Remain Attractive Market
The U.S. is expected to account for around one-third of the total share in the global benzodiazepine drugs market by 2026. Growing prevalence of anxiety...
Drug Research
Regeneron Announces Expanded Collaboration with HHS to Develop Antibody Treatments for New Coronavirus
Regeneron announced an expanded agreement with the U.S. Department of Health and Human Services (HHS) to develop new treatments combating the novel coronavirus, 2019-nCoV, which...
Drug Research
Aimmune secures $200m funding from Nestle Health Science
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that Nestlé Health Science will make...
Drug Research
Grey Wolf completes £2.5m Series A2 financing for development of therapies targeting ERAP2
Grey Wolf Therapeutics, a drug discovery biotechnology company focused on developing first-in-class therapies for immuno-oncology (IO), announces it has completed a £2.5 million ($3.3 million)...
Drug Research
New Velesco Pharma clinical manufacturing facility begins operations
Pharmaceutical development expert, Velesco Pharma, is initiating operations at its new state-of-the-art cGMP clinical manufacturing facility in Wixom, Michigan.
Set to triple the company’s cGMP clinical...
Drug Research
Eisai’s DAYVIGO gets approval in Japan to treat insomnia
Eisai Co., Ltd. announced that it has obtained the manufacturing and marketing approval in Japan for its in-house discovered orexin receptor antagonist DAYVIGO (2.5mg, 5mg,...
Drug Research
Eisai Commences Joint Research and Development of Cancer Gene Panel Test With Personal Genome Diagnostics Inc
Eisai Co., Ltd. announced that it has entered into a joint research and development agreement with Personal Genome Diagnostics Inc. for the cancer genetics panel...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.